Pharma News

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat CNS disorders, announced that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MIN-101, a first-in-class 5-HT2a and sigma2 antagonist in clinical development for the treatment of schizophrenia.

Pluristem Therapeutics Inc.,  a leading developer of placenta-based cell therapy products, announced that the U.S. Food and Drug Administration has granted the Company’s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Preeclampsia is among the most common medical complications of pregnancy and a leading cause of premature births, stillbirths and neonatal and maternal deaths. There is no cure except delivery. Due to high risks to the mother, women diagnosed with severe preeclampsia are usually delivered promptly, even if the baby will be born prematurely and may suffer permanent disabilities as a result. Severe preeclampsia occurs in approximately 1% of pregnancies in Western countries.

The chance appearance of certain combinations of elements in the genome can lead to the generation of new genes that drive evolutionary innovation.

In experimental models of lung cancer, researchers have found that a combination of two drugs plus radiation can help treat resistant lung cancers which are susceptible to therapy.

[adsense:336x280:8701650588]

The humble saffron has come to rescue people who are at the risk of developing liver cancer. A biomolecule found in the golden spice is good for your liver, find the researchers.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that regarding the acquisition of Chinese generic pharmaceutical company Liaoning TianYi Biological Pharmaceutical Co., Ltd. (Location: Benxi, Liaoning Province, China) previously announced on November 27, 2015, the conditions of transfer have been arranged, including receiving a new business license from the regulatory authority in China, and the acquisition has been completed.

A gene-editing technique has shown promise in treating Duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy among boys which is characterised by progressive muscle degeneration and weakness.

Researchers have developed new polio vaccine strains that is particularly suitable for a post-eradication era as these strains appear both effective and unable to cause disease after accidental release.

Pharma major Cadila Healthcare on Thursday clarified that products from its Moraiya and Ahmedabad plants in Gujarat were safe in the market and effective.